The Trump administration’s new TrumpRx deal with Eli Lilly and Novo Nordisk will slash GLP-1 drug prices, including Ozempic, Wegovy, and Zepbound, to as low as $245 per dose for Medicare, Medicaid, and direct consumers.

President Donald Trump announced that his administration has finally struck a deal with Novo Nordisk and Eli Lilly to reduce the cost of their GLP-1 weight loss drugs, Wegovy and Zepbound. Currently,

The agreement, announced by the White House, potentially unlocks a major new market for the mega-blockbuster drugs.

Even after Trump’s new deal, obesity drugs are still too expensive.